InvestorsHub Logo
Followers 594
Posts 20577
Boards Moderated 0
Alias Born 02/01/2012

Re: manisero66 post# 5236

Monday, 12/19/2016 10:55:07 AM

Monday, December 19, 2016 10:55:07 AM

Post# of 8023
manisero66 welcome to the $VCEL MB and for sharing your thoughts.

Now that the FDA has approved MACI for knee ligaments reconstruction using the patients' own autologous stem cells, I expect a major impact on Sports medicine revenues where athletes around the world can more quickly be back in the lineups. A major injury in sports are knee injuries, which can require at least a year of surgery and rehabilitation.

IMO in 2017 $VCEL expands MACI with FDA approval for other other key mobility joints required for Athletic performances such as shoulder rotary cuffs, hips, elbows etc.

In time also $VCEL expands MACI to all ages especially seniors beyond 55 yrs of age just as $VCEL does successfully for DCM clinical trials.

$VCEL double digit PPS in 2017 and 2018 IMO are well within $VCEL scope as revenues will expand starting in Jan 2017 when MACI will be Commercially used by the newly trained surgeons in the USA.

I look forward as well that $VCEL MACI will be restarted in Europe, UK and have increased revenues from new discussions with the EMA and MHRA. In addition IMO all countries of the world will be negotiated with and install accelerated Clinical approvals.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VCEL News